Skip to main content

Table 2 Univariate and multivariate analyses of the prognostic factors of OS in AGC patients with SPM (n = 129)

From: Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

Variables

Univariate analysis

Multivariate analysis

HR

[95% CI]

p-value

HR

[95% CI]

p-value

Regimen

 FP (vs. F)

0.56

[0.39–0.82]

< 0.01

0.47

[0.31–0.72]

< 0.01

Age

 ≥65 (vs. < 65)

0.80

[0.55–1.17]

0.25

   

Sex

 Female (vs. male)

1.05

[0.72–1.54]

0.78

   

PS

 2–4 (vs. 0–1)

1.22

[0.83–1.79]

0.32

0.95

[0.62–1.48]

0.83

Histology

 Intestinal (vs. diffuse)

0.71

[0.43–1.19]

0.19

0.70

[0.41–1.19]

0.18

 Unknown (vs. diffuse)

NA

 

NA

NA

 

NA

Disease status

 Recurrent (vs. advanced)

0.58

[0.25–1.32]

0.19

0.86

[0.36–2.10]

0.75

Primary site

 GEJ (vs. stomach)

0.98

[0.40–2.41]

0.96

   

No. of metastatic sites

 ≥3 (vs. 1–2)

1.43

[0.92–2.23]

0.11

1.64

[0.97–2.76]

0.07

Target lesion

 Absence (vs. presence)

0.95

[0.65–1.38]

0.78

   

Subtype of SPM

 Inadequate oral intake (vs. massive ascites)

0.81

[0.52–1.29]

0.38

0.58

[0.33–1.00]

0.05

 Both (vs. massive ascites)

1.09

[0.69–1.71]

0.71

0.76

[0.44–1.29]

0.31

Serum albumin level

 < 3.1 g/ml (vs. > 3.1 g/ml)

1.42

[0.97–2.07]

0.07

1.43

[0.94–2.17]

0.09

  1. AGC advanced gastric cancer, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, GEJ gastroesophageal junction, HR hazard ratio, NA not assessed, OS overall survival, SPM severe peritoneal metastasis